Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) Short Interest Down 55.4% in June

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) was the recipient of a large drop in short interest during the month of June. As of June 15th, there was short interest totaling 17,654 shares, a drop of 55.4% from the May 31st total of 39,619 shares. Based on an average daily volume of 100,034 shares, the short-interest ratio is currently 0.2 days. Currently, 0.0% of the company’s shares are short sold.

Analyst Ratings Changes

Separately, Zacks Research upgraded Otsuka from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 31st. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold”.

Otsuka Stock Performance

OTSKY opened at $33.91 on Monday. The business has a fifty day moving average price of $34.44 and a 200 day moving average price of $32.62. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.17 and a quick ratio of 1.67. Otsuka has a 12 month low of $21.68 and a 12 month high of $37.52. The stock has a market capitalization of $36.43 billion and a price-to-earnings ratio of 14.31.

Otsuka (OTCMKTS:OTSKY) last posted its earnings results on Tuesday, April 28th. The company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.43 by $0.16. The firm had revenue of $3.96 billion for the quarter, compared to analyst estimates of $3.78 billion. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. Sell-side analysts expect that Otsuka will post 1.98 earnings per share for the current fiscal year.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.